SCHEMBL25344102

SCHEMBL25344102

COc1nccc(OC2CCC2)c1[N+](=O)[O-]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP19A1 P11511 4/20 0.39
LRRK2 Q5S007 3/20 0.39
ALDH1A1 P00352 2/20 0.37
PTGES O14684 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
PTGS1 P23219 1/20 0.37
CYP2C19 P33261 1/20 0.37
PTGS2 P35354 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PDE5A O76074 1/20 0.36
ACACB O00763 1/20 0.35
PDE4A P27815 3/20 0.35
SCD O00767 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29534561 0.94 MEN1 (0.42) MEN1KMT2ACYP19A1LRRK2ALDH1A1
SCHEMBL24344461 0.94 MEN1 (0.42) MEN1KMT2ACYP19A1LRRK2ALDH1A1
SCHEMBL21826840 0.82 KMT2A (0.56) MEN1KMT2AALDH1A1MAPT
SCHEMBL29513591 0.82 KMT2A (0.56) MEN1KMT2AALDH1A1MAPT
SCHEMBL25347949 0.76 LRRK2 (0.43) LRRK2ACACBPDE4APDE4DPDE4B
SCHEMBL25344006 0.76 LRRK2 (0.43) LRRK2ACACBPDE4APDE4DPDE4B
SCHEMBL4632183 0.71 MEN1 (0.46) MEN1KMT2AALDH1A1TSHR
SCHEMBL7222277 0.71 ALDH1A1 (0.47) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL7372433 0.71 MEN1 (0.46) MEN1KMT2AALDH1A1CYP3A4MAPT
SCHEMBL24344996 0.70 HCRTR1 (0.39) LRRK2ALDH1A1SMN1; SMN2PDE4APDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-02-08 US disclosed
EP-4225741-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES Enliven Therapeutics, Inc. (US) 2023-08-16 EP disclosed
CN-116438182-A 7-azaindole compounds for inhibiting BCR-ABL tyrosine kinase 活力疗法公司 2023-07-14 CN disclosed
WO-2022076973-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR MEN1 4375/4885KMT2A 411/4885CYP19A1 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.